Loading people...
Daniel O'Mahony is a Partner at Seroba Life Sciences, a leading European venture capital firm specializing in life sciences investments. He is known for his expertise in identifying and nurturing innovative companies in the therapeutics, diagnostics, and medical device sectors.
Daniel O'Mahony primarily invests in European life sciences companies, focusing on therapeutics, diagnostics, and medical devices. He seeks out innovative firms with strong scientific foundations and significant potential to address unmet medical needs.
Daniel O'Mahony works as a Partner at Seroba Life Sciences. Seroba is a European venture capital firm with offices in Dublin, Ireland, and other key European locations, dedicated to investing in the life sciences sector.
Daniel O'Mahony stands as a prominent Partner at Seroba Life Sciences, a leading European venture capital firm dedicated to advancing the life sciences sector. With a deep understanding of the intricate landscape of biotechnology and healthcare, Daniel plays a pivotal role in identifying and nurturing innovative companies poised to make a significant impact on global health.
As a Partner at Seroba Life Sciences, Daniel O'Mahony is central to the firm's investment strategy. He leverages his extensive expertise to evaluate promising early to mid-stage companies, assessing their scientific merit, market potential, and the strength of their management teams. His role extends beyond capital allocation; Daniel actively supports portfolio companies, often serving on their boards, providing invaluable strategic guidance from clinical development through to market entry and commercialization. His hands-on approach helps steer these ventures through critical growth phases, maximizing their chances of success.
Daniel O'Mahony's investment focus is primarily on European life sciences companies. He targets three key areas: novel therapeutics designed to address unmet medical needs, advanced diagnostics that improve patient outcomes through earlier and more accurate detection, and innovative medical devices that enhance treatment delivery and patient care. Seroba Life Sciences, under Daniel's guidance, seeks out companies with robust scientific foundations, strong intellectual property, and clear pathways to commercial viability, aiming to back technologies that can truly transform healthcare.
His impressive career background underpins his success in venture capital. Daniel O'Mahony joined Seroba Life Sciences in 2007, bringing a wealth of experience from both the public and private sectors. Prior to his tenure at Seroba, he was with Enterprise Ireland, where he managed a diverse portfolio of venture capital funds and direct investments across technology and life sciences. Earlier in his career, Daniel gained significant experience as a management consultant at Accenture. In this role, he specialized in strategy and technology projects for major pharmaceutical and healthcare clients, acquiring invaluable insights into the operational complexities and strategic challenges faced by the industry. Academically, Daniel holds a B.Sc. in Biotechnology from Dublin City University and an MBA from University College Dublin, providing him with a powerful blend of scientific understanding and business acumen.
Daniel's commitment to fostering innovation is evident through his involvement with numerous companies. He currently serves on the boards of innovative firms such as Complement Therapeutics, Perfuze, and Inotrem. His past board roles include successful ventures like Endotronix, Novus Therapeutics, and Vivasure Medical, showcasing a consistent track record of backing and guiding companies that achieve significant milestones. Daniel O'Mahony's strategic vision and extensive experience make him a crucial asset to Seroba Life Sciences and a significant contributor to the vibrant European life sciences ecosystem, continually seeking out and supporting companies poised to make a transformative impact on global health.
Daniel O'Mahony is a Partner at Seroba Life Sciences based in Dublin, Ireland. He holds a Ph.D. from University College Cork and a business degree in technology management from Smurfit Business School, previously working in corporate business development at Elan Corporation and technology transfer at the National University of Ireland. In his current role, he manages venture investments across the biotechnology and medical device sectors, recently helping close the firm's €123 million Seroba Fund IV in April 2024. O'Mahony currently sits on the boards of Atlantic Therapeutics, Perfuze, and ATXA Therapeutics, and previously served as a board observer for Covagen before its acquisition by Janssen, alongside Novate Medical prior to its purchase by BTG. His professional background centers on scaling early-stage European life sciences companies through strategic planning, intellectual property management, technology commercialization, and venture capital funding.
